Molecular Partners' Anticipated Investor Conferences
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a dynamic clinical-stage biotechnology firm, is gearing up to participate in two significant investor conferences. This is an exciting time as the company's management team prepares to share insights into their pioneering DARPin therapy innovations.
First Conference: H.C. Wainwright BioConnect
The first event on the agenda is the H.C. Wainwright 3rd Annual BioConnect Investor Conference, taking place at NASDAQ. This fireside chat is scheduled for May 20, 2025, beginning at 3:30 PM ET. Attendees will have the chance to hear directly from the management team about the latest updates in their therapeutic developments.
Second Conference: TD Cowen’s Oncology Innovation Summit
Following the BioConnect Conference, Molecular Partners will also host a session at TD Cowen’s 6th Annual Oncology Innovation Summit. This event is set to occur on May 28, 2025, starting at 10:00 AM ET. Through this fireside chat, the company aims to delve into advancements in oncology and highlight how their innovative therapies are addressing significant medical challenges.
Webcasting Availability
For those unable to attend in person, both conferences will be webcasted, providing a convenient way for investors and interested parties to stay informed. Webcasts will be available on the Molecular Partners website, under the investors tab, ensuring that everyone has access to key discussions and insights shared during these important events.
About Molecular Partners AG
Founded in 2004, Molecular Partners AG is at the forefront of biopharmaceutical innovation, focusing on the design and development of DARPin therapeutics, a new class of protein drugs. Their portfolio spans multiple stages of pre-clinical and clinical development, with a keen focus on oncology. The company’s unique approach leverages the natural advantages of DARPins to provide tailored solutions for patients facing unmet medical needs. Through collaborations with leading pharmaceutical companies, Molecular Partners is committed to delivering groundbreaking therapeutic options.
Innovations in DARPin Therapeutics
Molecular Partners is dedicated to transforming the landscape of medicine with their innovative DARPin therapy platform. Unlike traditional therapies, DARPins offer enhanced specificity and stability, making them a promising alternative for targeting various diseases. As they continue to advance their research and clinical trials, the company is positioned to make significant contributions to patient care, particularly in oncology.
Contact for Further Information
For more information regarding the upcoming conferences or company inquiries, interested parties may reach out to the following contacts:
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35
Frequently Asked Questions
What are the upcoming investor conferences for Molecular Partners?
Molecular Partners is participating in the H.C. Wainwright BioConnect Investor Conference and TD Cowen’s Oncology Innovation Summit.
When will the conferences take place?
The H.C. Wainwright conference is on May 20, 2025, and the TD Cowen Summit is on May 28, 2025.
Will the conferences be accessible online?
Yes, both conferences will be webcasted and available on the Molecular Partners website.
What is Molecular Partners focusing on in its research?
The company is concentrating on DARPin therapeutics, especially for oncology applications.
How can I contact Molecular Partners for more information?
You can reach out to Seth Lewis or Laura Jeanbart through the provided emails for further inquiries.
